Moderna’s RSV Shot Just Got a Big Boost

Moderna’s RSV vaccine just scored FDA approval for younger adults (18-59) with health issues—previously, it was only for those 60+. The move comes as RSV risks for under-60s are often overlooked, but a ton of people in that group have conditions that put them at risk. Meanwhile, vaccine policy is getting a shake-up with RFK Jr. bringing in new advisors (some anti-vax!), and Moderna’s stock is feeling the heat. Big pharma drama and health news all in one! #Moderna #RSV #FDA #Health #BodyHealth